Composition for treating ocular effects of diabetes

A method for treating ocular effects of diabetes, comprising the step of administering an effective amount of a topical composition to a patient's eye, wherein the effect is inhibiting the formation and progression of defects of the cornea and conjunctiva, diabetic cataracts, and diabetic retinopathy, the topical composition comprising:

• a topical carrier having by weight about 0.4% carbomer, 4.0% sorbitol, 0.01% cetrimide, and 0.01% ethylenediaminetetraacetic acid, the balance being water;
• and
• an aldose reductase inhibitor mixed with the topical carrier to form an ophthalmic gel
• wherein the topical carrier has a viscosity of about 1,928 cps prior to admixture with the aldose reductase inhibitor, and
• wherein the aldose reductase inhibitor has a standardized particle size of less than 10 microns.

A method for treating ocular effects of diabetes, comprising the step of administering an effective amount of a topical composition to a patient's eye, wherein the effect is treatment of defects of the cornea and conjunctiva, diabetic cataracts, and diabetic retinopathy, the topical composition comprising:

• a topical carrier having by weight about 0.4% carbomer, 4.0% sorbitol, 0.01% cetrimide, and 0.01% ethylenediaminetetraacetic acid, the balance being water;
• and
• an aldose reductase inhibitor mixed with the topical carrier to form an ophthalmic gel,
• wherein the topical carrier has a viscosity of about 1,928 cps prior to admixture with the aldose reductase inhibitor, and
• wherein the aldose reductase inhibitor has a standardized particle size of less than 10 microns.